Cerebellum-based Imaging Neural Markers for Antipsychotic Response

ClinicalTrials.gov ID: NCT07483294

Open the official record

This page only displays public information reproduced from the official ClinicalTrials.gov record NCT07483294. It adds no medical advice, opinions, or eligibility judgments. The official record remains the source of truth for eligibility criteria, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:27 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Cerebellar-cortical Circuitry and Prediction of Treatment Response in Early Psychosis

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This study plans to collect 120 patients with first-episode psychosis. Participants will receive multimodal MRI scans (naturalistic fMRI, structural, diffusional) and comprehensive clinical assessments at baseline, and subsequently be treated with either risperidone or aripiprazole for 12 weeks. Clinical assessments for psychotic symptoms will be followed multiple times during the treatment until the 12th week. Data analysis will be conducted at the Psychiatric Research Unit of the Zucker Hillside Hospital.

Study identification

NCT ID: NCT07483294
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 4
Lead sponsor: Northwell Health; Other
Enrollment: 120 participants

Conditions and interventions

Conditions

Psychosis; Acute

Interventions

risperidone Drug
aripiprazole Drug

Drug

Eligibility (public fields only)

Age range: 15 Years to 40 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 1, 2025 (Actual)
Primary completion: Dec 1, 2029 (Estimated)
Completion: Jun 1, 2030 (Estimated)
Last update posted: May 26, 2026

2025 – 2030

United States locations

U.S. sites: 1
U.S. states: 1
U.S. cities: 1

Facility	City	State	ZIP	Site status
Zucker Hillside Hospital	Glen Oaks	New York	11004	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07483294, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 26, 2026 · Synced Nov 14, 2026